Disorders occurring in the central and peripheral nervous system comprise of neurological disorders. These disorders include Alzheimer disease, dementias, cerebrovascular disease, Parkinson’s disease, and traumatic disorder. It is assessed that more than 6 million people die because of stroke each year and an astonishing figure of 80% is that from developing and poor countries.
Lack of proper medications and knowledge, in regards, to neurological disorder causes increasing mortality rate every year. Thus, FDA has approved some widely accepted drugs termed to be a named patient medicine, as the medicines are frequently not available in the underdeveloped and developing countries.
Xadago, an orally administered medicine for the patients suffering from Parkinson’s disease is recommended from 100 mg to 50 mg as per the condition of the patient. It inhibits MAO-B activity after hindering the catabolism of dopamine and thus acting as a mechanical obstruct for Parkinson disease.
Also, Banzel, a triazole derivative is an indicative treatment drug for Seizures allied with Lennox Gastaut syndrome, which is common among children above 4 years and then into adults. The prescribed initial dose per day ranges from 400 mg to 800 mg and a maximum dose of 3200 mg per day. Although the exact mechanism of Banzel is unknown, yet the rufinamide modulates the activity of sodium channels which, in turn, slows down the seizures and its aligned symptoms.
The pharmaceutical consulting services allow the neurology department and its named patient program to export these medicines worldwide, with all its approvals and advancement to cure the fatal diseases like Parkinson and Lennox Gastaut syndrome.
